 BOSTON, Nov. 16, 2021 GLOBE NEWSWIRE -- Yumanity Therapeutics NASDAQ: YMTX, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will be presenting at the following investor conferences in November. He will discuss the results of the recently completed Phase 1b study of YTX-7739 in patients with Parkinsons disease and the development strategy going forward. 